ArticleFrontiers in immunology2026
Two cases of probable Neuro-Behçet syndrome treated with autologous HSCT.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-Behçet syndrome (NBS) is a rare but detrimental neurological manifestation of the Behçet syndrome (BS) - a chronic multisystemic inflammatory disease. NBS is frequently associated with brainstem and spinal cord lesions, often resulting in substantial neurological disability. Atypical clinical presentations can pose significant challenges for diagnosis and treatment of NBS. Here, we report the clinical course, treatment strategies and responses of two cases with probable NBS. Both cases presented with longitudinally extensive transverse myelitis and brainstem lesions and experienced recurrent relapses as well as disease progression resistant to multiple immunotherapies. Autologous hematopoietic stem cell transplantation (aHSCT) was without beneficial effect on the disease course in both cases. In summary, NBS or probable NBS should be considered in patients with myelitis and brainstem involvement with limited treatment response. These cases illustrate diagnostic challenges and limitations of current diagnostic criteria, while also underscoring the heterogeneity of disease presentation. Immune reset by aHSCT failed to confer clinical benefit as a rescue therapy in these two patients. Further studies are required to optimize therapeutic strategies for NBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.